X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (34) 34
humans (34) 34
middle aged (32) 32
oncology (29) 29
adult (28) 28
aged (28) 28
index medicus (26) 26
breast cancer (25) 25
chemotherapy (21) 21
cancer (19) 19
prognosis (18) 18
paclitaxel (15) 15
research (15) 15
treatment outcome (15) 15
breast neoplasms - drug therapy (14) 14
breast neoplasms - pathology (14) 14
immunohistochemistry (14) 14
medicine (13) 13
research article (13) 13
young adult (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
clinical trials (12) 12
breast neoplasms - genetics (10) 10
neoplasm staging (10) 10
carcinoma (9) 9
chemotherapy, adjuvant (9) 9
genetic aspects (9) 9
health aspects (9) 9
hospitals (9) 9
ovarian cancer (9) 9
receptor, erbb-2 - metabolism (9) 9
aged, 80 and over (8) 8
anthracyclines (8) 8
breast neoplasms - mortality (8) 8
disease-free survival (8) 8
epirubicin (8) 8
genetics (8) 8
medical research (8) 8
trastuzumab (8) 8
analysis (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
biomarkers, tumor - metabolism (7) 7
care and treatment (7) 7
dense sequential chemotherapy (7) 7
drug therapy (7) 7
mutation (7) 7
oncology, experimental (7) 7
paclitaxel - administration & dosage (7) 7
patients (7) 7
randomized phase-iii (7) 7
risk factors (7) 7
studies (7) 7
therapy (7) 7
tumors (7) 7
breast (6) 6
breast neoplasms - metabolism (6) 6
cancer patients (6) 6
erbb-2 protein (6) 6
expression (6) 6
fluorouracil - administration & dosage (6) 6
gene expression regulation, neoplastic (6) 6
kaplan-meier estimate (6) 6
multidisciplinary sciences (6) 6
pathology (6) 6
proportional hazards models (6) 6
retrospective studies (6) 6
rna, messenger - genetics (6) 6
rna, messenger - metabolism (6) 6
science (6) 6
adjuvant treatment (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
cancer research (5) 5
cancer therapies (5) 5
cyclophosphamide (5) 5
drug administration schedule (5) 5
drug dosages (5) 5
estrogen-receptor (5) 5
gene amplification (5) 5
genes (5) 5
greece (5) 5
male (5) 5
multivariate analysis (5) 5
product development (5) 5
protein expression (5) 5
receptor, erbb-2 - genetics (5) 5
survival (5) 5
taxanes (5) 5
tissue microarrays (5) 5
adjuvant chemotherapy (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - therapeutic use (4) 4
biomarkers (4) 4
biomarkers, tumor - genetics (4) 4
breast neoplasms - diagnosis (4) 4
breast tumors (4) 4
cancer treatment (4) 4
cancers and neoplasms (4) 4
carboplatin - administration & dosage (4) 4
cooperative oncology group (4) 4
cyclophosphamide - administration & dosage (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CANCER GENOMICS & PROTEOMICS, ISSN 1109-6535, 05/2019, Volume 16, Issue 3, pp. 195 - 206
Background/Aim: PTEN-loss and PIK3CA mutations have been addressed as markers of PI3K activation in breast cancer. We evaluated these markers in early... 
adjuvant chemotherapy | PTEN immunohistochemistry | ACTIVATION | MARKER | PHOSPHATASE | discordance | heterogeneity | CHEMOTHERAPY | trastuzumab | LAPATINIB | BENEFIT | HER2-positive breast cancer | ONCOLOGY | PATHWAY | GENETICS & HEREDITY | RESISTANCE | PI3K pathway | EXPRESSION | Carcinoma, Ductal, Breast - genetics | Carcinoma, Lobular - pathology | Receptors, Estrogen - metabolism | Class I Phosphatidylinositol 3-Kinases - genetics | Prognosis | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Neoplasm Recurrence, Local - drug therapy | Receptors, Progesterone - metabolism | Neoplasm Recurrence, Local - pathology | Carcinoma, Ductal, Breast - drug therapy | Carcinoma, Lobular - genetics | Carcinoma, Ductal, Breast - pathology | Female | PTEN Phosphohydrolase - genetics | Survival Rate | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoplasm Recurrence, Local - genetics | Biomarkers, Tumor - genetics | Carcinoma, Lobular - drug therapy | Mutation | Cohort Studies | Immunohistochemistry | Medical research | Evaluation | Risk groups | Markers | Health risks | Clinical trials | Risk | Breast cancer | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Heterogeneity | Chemotherapy | Breast | PTEN protein | Tumors
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2014, Volume 9, Issue 3, p. e91407
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, p. e69256
To explore the activity and safety of two schedules of ixabepilone, as first line chemotherapy, in patients with metastatic breast cancer previously treated... 
MICROTUBULE-STABILIZING AGENTS | PLUS CAPECITABINE | EPOTHILONE-B ANALOG | CLINICAL-TRIAL | MESSENGER-RNA EXPRESSION | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | PERIPHERAL NEUROPATHY | PROGESTERONE-RECEPTOR | MISMATCH REPAIR PROTEINS | ESTROGEN-RECEPTOR | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Epothilones - pharmacology | Tubulin - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Epothilones - therapeutic use | RNA, Messenger - metabolism | Epothilones - adverse effects | Neoplasm Metastasis | Tubulin - metabolism | Antineoplastic Agents - adverse effects | Biomarkers, Tumor - metabolism | Adult | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Drug Administration Schedule | RNA, Messenger - genetics | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Epothilones - administration & dosage | Aged | Patient Compliance | Medical research | Care and treatment | RNA | Clinical trials | Breast cancer | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Chemotherapy | Medicine, Experimental | Product development | Cancer | Schedules | Toxicity | Oncology | Single-nucleotide polymorphism | Neuropathy | Multivariate analysis | Cancer therapies | Metastases | Ovarian cancer | Proteins | Randomization | Safety management | Cell cycle | Peripheral blood | Drug dosages | Deoxyribonucleic acid--DNA | Neutropenia | Markers | FDA approval | Group dynamics | Gene expression | Patients | Survival | ErbB-2 protein | Medicine | Pathology | Hospitals | Tau protein | Deoxyribonucleic acid | DNA
Journal Article
BMC Cancer, ISSN 1471-2407, 06/2012, Volume 12, Issue 1, pp. 271 - 271
Background: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal... 
Irinotecan | Chemotherapy | Capecitabine | Angiogenic markers | Colorectal cancer | Bevacizumab | COLON-CANCER | OSTEOPONTIN | ONCOLOGY | NITRIC-OXIDE | ORAL FLUOROPYRIMIDINES | BICC-C | EXPRESSION | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Osteopontin - blood | Leucovorin - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Biomarkers - blood | Angiogenic Proteins - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Care and treatment | Patient outcomes | Research | Comparative analysis | Cancer | Clinical trials | Leucovorin | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Nitric oxide | Product development | Vascular endothelial growth factor | Growth factors
Journal Article
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 01/2012, Volume 10, Issue 1, pp. 10 - 10
Background: HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with... 
Mrna expression | Anthracyclines | Gene amplification | Top2a | Randomized study | Cish | Early breast cancer | Taxanes | Her2 | TOP2A | early breast cancer | PREDICTIVE MARKERS | MEDICINE, RESEARCH & EXPERIMENTAL | CISH | TOPOISOMERASE-II-ALPHA | taxanes | IN-SITU HYBRIDIZATION | QUANTITATIVE PCR | ESTROGEN-RECEPTOR | mRNA expression | PARAFFIN-EMBEDDED TISSUE | MESSENGER-RNA | PROTEIN EXPRESSION | CELL-CYCLE | anthracyclines | HER2 | gene amplification | randomized study | Multivariate Analysis | Receptors, Estrogen - metabolism | Antibiotics, Antineoplastic - pharmacology | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Ki-67 Antigen - metabolism | Gene Expression Profiling | RNA, Messenger - metabolism | Receptors, Progesterone - metabolism | DNA-Binding Proteins - metabolism | Dose-Response Relationship, Drug | Paraffin Embedding | Young Adult | Poly-ADP-Ribose Binding Proteins | Breast Neoplasms - enzymology | Antigens, Neoplasm - metabolism | Adult | Female | Chemotherapy, Adjuvant | Gene Expression Regulation, Neoplastic - drug effects | Tissue Fixation | Genes, Neoplasm - genetics | Antigens, Neoplasm - genetics | DNA Topoisomerases, Type II - metabolism | RNA, Messenger - genetics | Risk Factors | Proportional Hazards Models | Treatment Outcome | DNA-Binding Proteins - genetics | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Antibiotics, Antineoplastic - therapeutic use | Breast Neoplasms - pathology | Epirubicin - therapeutic use | DNA Topoisomerases, Type II - genetics | Aged | Epirubicin - pharmacology | Genes | Physiological aspects | Breast cancer | Genetic aspects | Research | Epirubicin | Drug therapy | Health aspects | DNA topoisomerase II | Medical research | Oncology | Cytotoxicity | Cancer therapies | Manuscripts | Medicine | Pathology | Chemotherapy | Hospitals | Writing | Drug dosages | Tumors
Journal Article
Chemotherapy research and practice, ISSN 2090-2107, 2011, Volume 2011, pp. 878912 - 8
Glioblastoma is the most common malignant glioma in adults, and despite recent advances in standard treatment, the prognosis still remains dismal, with a... 
Review
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 538 - 538
Background - Aim: Nodal status and stromal tumor infiltrating lymphocyte (TILs) density are independently associated with patient outcome in triple-negative... 
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2012, Volume 134, Issue 1, pp. 353 - 362
In spite the close association of the triple-negative breast cancer immunophenotype with hereditary breast cancers and the BRCA1 pathway, there is a lack of... 
Oncology | Hereditary breast–ovarian cancer | BRCA1 | Genetic testing | Medicine & Public Health | Triple-negative breast cancer | Hereditary breast-ovarian cancer | GENOMIC REARRANGEMENTS | FOUNDER MUTATIONS | ESTROGEN-RECEPTOR | PACLITAXEL | EPIRUBICIN | ONCOLOGY | RANDOMIZED PHASE-III | GERMLINE MUTATIONS | DENSE SEQUENTIAL CHEMOTHERAPY | YOUNG-WOMEN | CMF | Carcinoma, Ductal, Breast - genetics | Receptors, Estrogen - metabolism | Carcinoma, Ductal, Breast - epidemiology | Genetic Testing | Prevalence | Hereditary Breast and Ovarian Cancer Syndrome - diagnosis | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Carcinoma, Lobular - epidemiology | Hereditary Breast and Ovarian Cancer Syndrome - metabolism | Patient Selection | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Lobular - genetics | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Carcinoma, Ductal, Breast - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - genetics | Carcinoma, Lobular - diagnosis | Carcinoma, Ductal, Breast - diagnosis | BRCA1 Protein - genetics | Heterozygote | Aged | Carcinoma, Lobular - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - epidemiology | Mutation | BRCA mutations | Oncology, Experimental | Breast cancer | Research | Toy industry | Genetic screening | Prevalence studies (Epidemiology) | Ovarian cancer | Analysis | DNA | Genetic aspects | Diagnosis | Cancer
Journal Article
Journal Article
Journal Article